Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 305

[40] Steiner MS, Gingrich JR, Chauhan RD. Prostate cancer gene therapy. Surg Oncol Clin N
Am 2002;11:607-20.
[41] Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Des 2003;9:455-66.
[42] Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, et al. Prostate cancer gene
therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclo-
vir in mouse and human prostate cancer models. Hum Gene Ther 1996;7:515-23.
[43] Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral-mediated transfer of a
heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998;58:
1358-62.
[44] Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In
situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene
Ther 1999;10:1239-49.
[45] Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, et al. Prostate-
specific antigen response and systemic T cell activation after in situ gene therapy in pros-
tate cancer patients failing radiotherapy. Hum Gene Ther 2001;12:1955-67.
[46] Teh BS, Aguilar CE, Kernen K, Chou CC, Shalev M, Vlachaki MT, et al. Phase I/II trial
evaluating combined radiotherapy and in situ gene therapy with or without hormonal
therapy in the treatment of prostate cancer—a preliminary report. Int J Radiat Oncol Biol
Phys 2001;51:605-13.
[47] Kato H, Koshida K, Yokoyama K, Mizokami A, Namiki M. Potential benefits of combin-
ing cytosine deaminase/ 5-fluorocytosine gene therapy and irradiation for prostate can-
cer: experimental study. Int J Urol 2002;9:567-76.
[48] Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, et al.
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy
for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
[49] Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumor cell killing
in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin
Cancer Res 1997;3:2075-80.
[50] Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al.
Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory
prostate cancer. J Urol 1995;154:414-21.
[51] Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy
with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5.
[52] Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Cytotoxic effects of recombi-
nant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in
human prostate cancers. J Urol 1997;158:636-41.
[53] Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, et al. Adenovirus mediated Bax over-
expression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res
2001;61:186-91.
[54] Lowe SL, Rubinchik S, Honda T, Mcdonnell TJ, Dong JY, Norris JS. Prostate-specific
expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate
cancer cells. Gene Ther 2001;8:1363-71.
[55] Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, et al. Adenovirus-mediated
transfer of inducible caspases: a novel “death switch” gene therapeutic approach to pros-
tate cancer. Cancer Res 2001;61:2562-71.
[56] Zhang Y, Yu J, Unni E, Shao TC, Nan B, Snabboon T, et al. Monogene and polygene ther-
apy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad
driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther 2002;13:2051-64.